To compare long-term intraocular pressure (IOP)-lowering efficacy of 0.25% and 0.5% apraclonidine hydrochloride with 0.5% timolol maleate.
Multicenter, randomized, double-masked trial. Adult patients of either sex diagnosed as having open-angle glaucoma or ocular hypertension were enrolled following appropriate washout from all ocular hypotensive medications. Morning IOPs of 22 to 35 mm Hg were required for entry. Patients received 0.25% or 0.5% apraclonidine 3 times a day or 0.5% timolol twice a day for 90 days. Intraocular pressure was measured at 8 am (before morning dosing) and at 4 pm (8 hours after dosing) on days 1, 30, and 90, and only at 8 am on day 14.
All 3 medications significantly reduced IOP from baseline at all observation times (P<.001): 0.5% apraclonidine reduced IOP more than 0.25% apraclonidine; no significant difference was observed between 0.5% apraclonidine and 0.5% timolol 8 hours after dosing on days 1, 30, and 90; and a significant difference (P<.05) in favor of 0.5% timolol over 0.25% apraclonidine was observed 8 hours after dosing on day 30. At all morning visits following evening dosing, 0.5% timolol significantly reduced IOP more than both concentrations of apraclonidine.
Both 0.25% and 0.5% apraclonidine significantly reduce IOP when used as primary ocular hypotensive medication. Although 0.25% and 0.5% apraclonidine reduce IOP to a similar degree as 0.5% timolol 8 hours after morning dosing, neither concentration is as effective for reducing morning IOP after evening dosing.
Stewart WC, Laibovitz R, Horwitz B, Stewart RH, Ritch R, Kottler M. A 90-Day Study of the Efficacy and Side Effects of 0.25% and 0.5% Apraclonidine vs 0.5% Timolol. Arch Ophthalmol. 1996;114(8):938–942. doi:10.1001/archopht.1996.01100140146006
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.